Salmon calcitonin: a review of current and future therapeutic indications
The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“sCT has much higher biological potency in humans than hCT, and has, by far, been the most widely used preparation in clinical practice (33).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [33]
In the citing paper
“sCT was first introduced to the market in 1974 and was subsequently approved by the United States Food and Drug Administra-tion for use in the treatment of postmenopausal osteoporosis, hypercalcemia, and Paget's disease (33,165).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [33]
In the citing paper
“sCT was effective in inhibiting bone turnover, providing pain relief, and improving bone structure, healing osteolytic lesions and supporting the formation of normal lamellar bone (33).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [33]
In the citing paper
“A number of small studies of intranasal or subcutaneous use of sCT showed increases in bone density, reduced number of vertebral fractures, and an association with reduction of the risk of hip fracture (26, 33, 110, 139), whereas others found no bone effects (12).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [33]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475
Self-citation(2020) · Elsevier eBooks · doi:10.1016/c2015-1-01622-2 · Cited by 1,683
Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., Cannata, J., Balogh, A., Lemmel, E.-M., Pors-Nielsen, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa022436 · Cited by 1,638
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229 · cited 1×
“Similar subgroup analyses regarding the potential for non-vertebral fracture risk reduction have been used and validated as an appropriate analysis in other trials of osteoporosis trials on antiresorptive agents [50, 51].”
MethodSelf-citationChesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122 · cited 4×
“However the number of fractures in this study was small, and the main evidence for the antifracture efficacy of SCT-NS is derived from the PROOF study [28], which was a confirmative large-scale multicenter trial initiated in 1991.”
BackgroundMethodInfluentialSelf-citationPrevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 1×
“The existence of calcitonin receptors on osteoblasts has been suggested [21–24], and findings in some clinical trials have indicated a possible stimulatory effect on bone formation.”
BackgroundDelmas, P. D., Genant, H. K., Crans, G. G., Stock, J. L., Wong, M., Siris, E., & Adachi, J. D. (2003) · Bone · doi:10.1016/s8756-3282(03)00241-2 · Cited by 545 · cited 1×
“Similar subgroup analyses regarding the potential for non-vertebral fracture risk reduction have been used and validated as an appropriate analysis in other trials of osteoporosis trials on antiresorptive agents [50, 51].”
MethodCalcitonin alters behaviour of isolated osteoclasts
Chambers, T. J., & Magnus, C. J. (1982) · The Journal of Pathology · doi:10.1002/path.1711360104 · Cited by 504 · cited 1×
“Flattening of the osteoclast ruffled borders and withdrawal of osteoclasts from sites of active bone resorption occurs upon exposure to calcitonin in vitro [14–18].”
BackgroundNicholson, G. C., Moseley, J. M., Sexton, P. M., Mendelsohn, F. A., & Martin, T. J. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112584 · Cited by 454 · cited 1×
“It has been estimated that one osteoclast holds approximately one million calcitonin receptors [13].”
BackgroundSarkar, S., Mitlak, B. H., Wong, M., Stock, J. L., Black, D. M., & Harper, K. D. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.1 · Cited by 442 · cited 1×
“As an example, post hoc analyses from the MORE study [54] have demonstrated a striking discordance between changes in BMD and treatment associated fracture risk reduction.”
MethodOvergaard, K., Hansen, M. A., Jensen, S. B., & Christiansen, C. (1992) · BMJ · doi:10.1136/bmj.305.6853.556 · Cited by 426 · cited 1×
“The aforementioned Overgaard study [45] noted a significant (p=0.”
BackgroundBone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
Civitelli, R., Gonnelli, S., Zacchei, F., Bigazzi, S., Vattimo, A., Avioli, L. V., & Gennari, C. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113725 · Cited by 358 · cited 1×
“[42] reported that a higher level of baseline bone resorption did result in greater increases in spine bone mineral content for injectable calcitonin.”
BackgroundHoltrop, M. E., Raisz, L. G., & Simmons, H. A. (1974) · The Journal of Cell Biology · doi:10.1083/jcb.60.2.346 · Cited by 342
Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.
Kanis, J. A., Johnell, O., Gullberg, B., Allander, E., Dilşen, G., Gennari, C., Lopes Vaz, A. A., Lyritis, G. P., Mazzuoli, G., & Miravet, L. (1992) · BMJ · doi:10.1136/bmj.305.6862.1124 · Cited by 285 · cited 1×
“Efficacy in vertebral fracture risk reduction was shown in one randomized, controlled clinical trial [34]; risk reduction in hip fractures was reported in the retrospective Mediterranean Osteoporosis study [37].”
BackgroundAdjuvant Analgesics in Cancer Pain Management
Lussier, D., Huskey, A. G., & Portenoy, R. K. (2004) · The Oncologist · doi:10.1634/theoncologist.9-5-571 · Cited by 249 · cited 1×
“Injectable salmon calcitonin has been shown to be superior to placebo in acute vertebral fractures [84], and has shown analgesic effects in metastatic bone disease [85, 86] and in complex regional pain syndrome type I [87].”
BackgroundMazzuoli, G. F., Passeri, M., Gennari, C., Minisola, S., Antonelli, R., Valtorta, C., Palummeri, E., Cervellin, G. F., Gonnelli, S., & Francini, G. (1986) · Calcified Tissue International · doi:10.1007/bf02556587 · Cited by 218 · cited 1×
“Effects on lumbar spine BMD have been reported in a number of smaller controlled clinical trials [34–36].”
BackgroundAtamas, S. P., Yurovsky, V. V., Wise, R. A., Wigley, F. M., Robinson, C. J. G., Henry, P. A., Alms, W. J., & White, B. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1119::aid-anr8>3.0.co;2-3 · Cited by 216
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene
Hoff, A. O., Catala-Lehnen, P., Thomas, P. M., Priemel, M., Rueger, J. M., Nasonkin, I., Bradley, A., Hughes, M. R., Ordonez, N., Cote, G. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200214218 · Cited by 209 · cited 1×
“orated [ 5 ], and no bone pathologies have been associated with hypo- or hypersecretion of calcitonin in humans [6].”
BackgroundFischer, J. A., Tobler, P. H., Kaufmann, M., Born, W., Henke, H., Cooper, P. E., Sagar, S. M., & Martin, J. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.12.7801 · Cited by 201 · cited 1×
“Numerous calcitonin binding sites have been detected in the CNS, especially in the hypothalamus [78–80], and it is therefore assumed that the analgesic effects of salmon calcitonin are at least to some extent mediated centrally, with serotonergic pathways involved [81–83].”
BackgroundThe Sensitivity of Isolated Osteoclasts to Morphological Transformation by Calcitonin*
CHAMBERS, T. J., & MOORE, A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-4-819 · Cited by 195 · cited 1×
“Flattening of the osteoclast ruffled borders and withdrawal of osteoclasts from sites of active bone resorption occurs upon exposure to calcitonin in vitro [14–18].”
BackgroundTreatment of Reflex Sympathetic Dystrophy (CRPS Type 1)
Perez, R. S. G. M., Kwakkel, G., Zuurmond, W. W. A., & de Lange, J. J. (2001) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(01)00282-2 · Cited by 192 · cited 1×
“Injectable salmon calcitonin has been shown to be superior to placebo in acute vertebral fractures [84], and has shown analgesic effects in metastatic bone disease [85, 86] and in complex regional pain syndrome type I [87].”
BackgroundEffect of salcatonin given intranasally on early postmenopausal bone loss.
Overgaard, K., Riis, B. J., Christiansen, C., & Hansen, M. A. (1989) · BMJ · doi:10.1136/bmj.299.6697.477 · Cited by 179 · cited 1×
“Studies in early menopausal women have typically shown a stabilization of BMD at the lumbar spine [46, 47].”
BackgroundLyritis, G. P., Tsakalakos, N., Magiasis, B., Karachalios, T., Yiatzides, A., & Tsekoura, M. (1991) · Calcified Tissue International · doi:10.1007/bf02555844 · Cited by 177 · cited 1×
“Injectable salmon calcitonin has been shown to be superior to placebo in acute vertebral fractures [84], and has shown analgesic effects in metastatic bone disease [85, 86] and in complex regional pain syndrome type I [87].”
BackgroundBorah, B., Dufresne, T. E., Chmielewski, P. A., Johnson, T. D., Chines, A., & Manhart, M. D. (2004) · Bone · doi:10.1016/j.bone.2003.12.013 · Cited by 176 · cited 1×
“As noted in Table 1, preservation of trabecular microarchitecture is to date confirmed only for SCT-NS and risedronate [38, 62].”
BackgroundMechanism of osteoclast mediated bone resorption—rationale for the design of new therapeutics
VAANANEN, K. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.018 · Cited by 176 · cited 1×
“Cell apoptosis has not been observed with calcitonin for either osteoclasts, osteoblasts or osteocytes [19, 20].”
BackgroundNASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSIS
OVERGAARD, K., RIIS, B. J., CHRISTIANSEN, C., PØADENPHANT, J., & JOHANSEN, J. S. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb00443.x · Cited by 169 · cited 1×
“baseline in lumbar spine BMD [44].”
Pun, K. K., & Chan, L. W. (1989) · PubMed · Cited by 165
Marcus, R., Wong, M., Heath, H., & Stock, J. L. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0453 · Cited by 164
Chesnut, C. H., Majumdar, S., Newitt, D. C., Shields, A., Van Pelt, J., Laschansky, E., Azria, M., Kriegman, A., Olson, M., Eriksen, E. F., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050411 · Cited by 163 · cited 14×
“SerumCTX-1 reductions vs. placebo were 25.5% at 2 years in the Qualitative Effects of Salmon Calcitonin study (QUEST) [38] (p=0.02; last observation carried forward analysis) and 12.3% at 5 years in the Prevent Recurrence of Osteoporotic Fracture study (PROOF) (p<0.01) for the 200 IU/d dose groups [28].”
BackgroundMethodInfluentialSelf-citationMaricic, M., Adachi, J. D., Sarkar, S., Wu, W., Wong, M., & Harper, K. D. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1140 · Cited by 161
Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS
Zaidi, M., Inzerillo, A. M., Moonga, B. S., Bevis, P. J. R., & Huang, C. L.-H. (2002) · Bone · doi:10.1016/s8756-3282(02)00688-9 · Cited by 151 · cited 1×
“Flattening of the osteoclast ruffled borders and withdrawal of osteoclasts from sites of active bone resorption occurs upon exposure to calcitonin in vitro [14–18].”
BackgroundKnopp‐Sihota, J., Diner, B. M., Blitz, M., Lyritis, G. P., & Rowe, B. H. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1798-8 · Cited by 143 · cited 1×
“35) [65, 66, 95–97].”
Lyritis, G. P., Paspati, I., Karachalios, T., Ioakimidis, D., Skarantavos, G., & Lyritis, P. G. (1997) · Acta Orthopaedica Scandinavica · doi:10.1080/17453674.1997.11744761 · Cited by 139 · cited 1×
“Male patients were also included within studies on the analgesic efficacy of SCT in vertebral fracture associated pain syndromes [65, 66].”
BackgroundAn evaluation of antibodies and clinical resistance to salmon calcitonin
Singer, F. R., Aldred, J. P., Neer, R. M., Krane, S. M., Potts, J. T., & Bloch, K. J. (1972) · Journal of Clinical Investigation · doi:10.1172/jci107044 · Cited by 138 · cited 1×
“In this regard it is also uncertain whether the development of calcitonin antibodies in response to calcitonin administration is of clinical relevance; differences in bioavailability of calcitonin across the differing preparations (nasal spray and parenteral) may result in differing antibody level production, with var…”
BackgroundPerspective: Reconsidering the Effects of Antiresorptive Therapies in Reducing Osteoporotic Fracture
Chesnut, C. H., & Rosen, C. J. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.12.2163 · Cited by 133 · cited 1×
“A more integrative concept has evolved, including material properties, bone turnover, bone geometry and bone microarchitecture as the determinants of bone quality and bone strength [52].”
BackgroundSelf-citationIs bone mineral density predictive of fracture risk reduction?
Cefalu, C. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003062 · Cited by 132 · cited 1×
“Doubts have emerged as to the abilitiy of BMD to predict and mediate fracture risk reduction in patients receiving antiresorptive therapy [53].”
BackgroundTakahashi, S., Goldring, S., Katz, M., Hilsenbeck, S., Williams, R., & Roodman, G. D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117634 · Cited by 125 · cited 1×
“Physiologic down-regulation of calcitonin receptor sites has been reported [26] but is of uncertain clinical significance.”
BackgroundManicourt, D.-H., Altman, R. D., Williams, J. M., Devogelaer, J.-P., Druetz-Van Egeren, A., Lenz, M. E., Pietryla, D., & Thonar, E. J.-M. A. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1159::aid-anr12>3.0.co;2-q · Cited by 122 · cited 1×
“[105] noted significant suppression of potentially deleterious effects of osteoarthritis on subchondral bone, cartilage, and synovia with SCT in dogs with experimentally induced osteoarthritis.”
BackgroundSalmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome
Rico, H., Hernández, E. R., Revilla, M., & Gómez-Castresana, F. (1992) · Bone and Mineral · doi:10.1016/0169-6009(92)90883-f · Cited by 110 · cited 1×
“Efficacy in vertebral fracture risk reduction was shown in one randomized, controlled clinical trial [34]; risk reduction in hip fractures was reported in the retrospective Mediterranean Osteoporosis study [37].”
BackgroundBagger, Y. Z., Tankó, L. B., Alexandersen, P., Karsdal, M. A., Olson, M., Mindeholm, L., Azria, M., & Christiansen, C. (2005) · Bone · doi:10.1016/j.bone.2005.04.032 · Cited by 109 · cited 2×
“In addition to the effects on bone turnover, recent data indicated a benefit of oral SCT in reducing cartilage degradation in osteoarthritis, as will be discussed subsequently [103].”
BackgroundSelf-citationDiscontinuous calcitonin treatment of established osteoporosis—effects of withdrawal of treatment
Overgaard, K., Hansen, M. A., Nielsen, V.-A. H., Riis, B. J., & Christiansen, C. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90089-v · Cited by 108 · cited 1×
“Bone turnover markers return to baseline levels within 3 months of SCT treatment discontinuation [41].”
BackgroundDr. Trovas, G. P., Lyritis, G. P., Galanos, A., Raptou, P., & Constantelou, E. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.3.521 · Cited by 107 · cited 1×
“In 2 placebocontrolled trials over 12 or 18 months (n=28 and n=40) [63, 64], SCT-NS led to statistically significant increases in lumbar spine BMD when compared to placebo.”
BackgroundLyritis, G. P., Ioannidis, G. V., Karachalios, T., Roidis, N., Kataxaki, E., Papaioannou, N., Kaloudis, J., & Galanos, A. (1999) · The Clinical Journal of Pain · doi:10.1097/00002508-199912000-00004 · Cited by 103 · cited 1×
“35) [65, 66, 95–97].”
Calcitonin for preventing and treating corticosteroid-induced osteoporosis
Cranney, A., Welch, V., Adachi, J., Homik, J., Shea, B., Suarez-Almazor, M. E., Tugwell, P., & Wells, G. A. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001983 · Cited by 102
Taboulet, J. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.13.2129 · Cited by 100 · cited 1×
“An association has also been described between specific calcitonin gene receptor genotypes and increased femoral neck BMD and reduced osteoporotic fracture risk in postmenopausal women [32].”
BackgroundBoonen, S., Body, J., Boutsen, Y., Devogelaer, J., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1812-1 · Cited by 96
Tankó, L. B., Bagger, Y. Z., Alexandersen, P., Devogelaer, J.-P., Reginster, J.-Y., Chick, R., Olson, M., Benmammar, H., Mindeholm, L., Azria, M., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040715 · Cited by 94 · cited 1×
“A more recent 3 months’ dose ranging study in 277 postmenopausal women confirmed the effective absorption from the gastrointestinal tract, resulting in dose-dependent, sustained responses in bone resorption markers [102].”
BackgroundSelf-citationThe effect of rectal and nasal administration of salmon calcitonin in normal subjects
Buclin, T., Randin, J. P., Jacquet, A. F., Azria, M., Attinger, M., Gomez, F., & Burckhardt, P. (1987) · Calcified Tissue International · doi:10.1007/bf02555225 · Cited by 93 · cited 1×
“In healthy subjects with normal calcium levels only subtle, transient calcium-lowering effects are observed following the administration of SCT [7, 8].”
BackgroundSelf-citationKittur, S. D., Hoppener, J. W., Antonarakis, S. E., Daniels, J. D., Meyers, D. A., Maestri, N. E., Jansen, M., Korneluk, R. G., Nelkin, B. D., & Kazazian, H. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.15.5064 · Cited by 91 · cited 1×
“The calcitonin gene complex (an α and β gene, including the calcitonin receptor gene), is located on chromosome 11 [29].”
BackgroundThe Analgesic Role of Calcitonin Following Osteoporotic Fracture
Silverman, S. L., & Azria, M. (2002) · Osteoporosis International · doi:10.1007/s001980200118 · Cited by 88 · cited 1×
“Numerous calcitonin binding sites have been detected in the CNS, especially in the hypothalamus [78–80], and it is therefore assumed that the analgesic effects of salmon calcitonin are at least to some extent mediated centrally, with serotonergic pathways involved [81–83].”
BackgroundSelf-citationCentral nervous system binding sites for calcitonin and calcitonin gene-related peptide
Sexton, P. M. (1991) · Molecular Neurobiology · doi:10.1007/bf02935550 · Cited by 87 · cited 1×
“Numerous calcitonin binding sites have been detected in the CNS, especially in the hypothalamus [78–80], and it is therefore assumed that the analgesic effects of salmon calcitonin are at least to some extent mediated centrally, with serotonergic pathways involved [81–83].”
BackgroundSalmon calcitonin in the acute management of hypercalcemia
Wisneski, L. A. (1990) · Calcified Tissue International · doi:10.1007/bf02553290 · Cited by 86 · cited 1×
“In these conditions, the calciumlowering effect of SCT is characterized by a rapid onset of action, i.e., usually within two hours [ 9 ].”
BackgroundDemonstration of a Hypocalcemic Factor (Calcitonin) in Commercial Parathyroid Extract
Copp, D. H., & Cameron, E. C. (1961) · Science · doi:10.1126/science.134.3495.2038 · Cited by 85 · cited 1×
“[1] in 1961 as a substance lowering blood calcium.”
Background25 Years of salmon calcitonin: From synthesis to therapeutic use
Azria, M., Copp, D. H., & Zanelli, J. M. (1995) · Calcified Tissue International · doi:10.1007/bf00301940 · Cited by 85 · cited 1×
“SCT is, by far, the most widely used preparation in clinical practice due to its 40-50 times higher intrinsic potency when compared to human calcitonin, and its improved analgesic properties [2].”
BackgroundSelf-citationFARLEY, J. R., TARBAUX, N. M., HALL, S. L., LINKHART, T. A., & BAYLINK, D. J. (1988) · Endocrinology · doi:10.1210/endo-123-1-159 · Cited by 85 · cited 1×
“The existence of calcitonin receptors on osteoblasts has been suggested [21–24], and findings in some clinical trials have indicated a possible stimulatory effect on bone formation.”
BackgroundBuclin, T., Rochat, M. C., Burckhardt, P., Azria, M., & Attinger, M. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.8.1478 · Cited by 83 · cited 1×
“An initial study in healthy subjects has demonstrated a rapid and reproducible dose-dependent increase in serum SCT levels after oral intake, with a corresponding biological response in markers of bone resorption [101].”
BackgroundSelf-citationCalcitonin Induced Increase in ACTH, β-Endorphin and Cortisol Secretion
Laurian, L., Oberman, Z., Graf, E., Gilad, S., Hoerer, E., & Simantov, R. (1986) · Hormone and Metabolic Research · doi:10.1055/s-2007-1012291 · Cited by 81 · cited 1×
“Numerous calcitonin binding sites have been detected in the CNS, especially in the hypothalamus [78–80], and it is therefore assumed that the analgesic effects of salmon calcitonin are at least to some extent mediated centrally, with serotonergic pathways involved [81–83].”
BackgroundTreatment of Paget's Disease of Bone with Synthetic Salmon Calcitonin
Kanis, J. А., Horn, D. B., Scott, R. D. M., & Strong, J. A. (1974) · BMJ · doi:10.1136/bmj.3.5933.727 · Cited by 81 · cited 1×
“SCT, which has been used for years in the treatment of Paget’s disease, either as injection or nasal spray, is a therapeutic alternative to bisphosphonates [68–70] The efficacy and safety of SCT in Paget’s disease was established in a number of primarily observational studies initiated in the 1970s and 1980s.”
BackgroundPlosker, G. L., & McTavish, D. (1996) · Drugs & Aging · doi:10.2165/00002512-199608050-00006 · Cited by 78
Quality-of-life issues in osteoporosis
Silverman, S. L. (2005) · Current Rheumatology Reports · doi:10.1007/s11926-005-0007-x · Cited by 77 · cited 1×
“As well, such impairment may be greater in elderly individuals [48].”
BackgroundSelf-citationRESNICK, D. L., & Kransdorf, M. J. (2005) · Elsevier eBooks · doi:10.1016/b0-7216-0270-3/50046-3 · Cited by 77
Effects of Calcitonin in Paget's Disease and Polyostotic Fibrous Dysplasia
Bell, N. H., Avery, S., & Johnston, C. C. (1970) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-31-3-283 · Cited by 74 · cited 1×
“SCT, which has been used for years in the treatment of Paget’s disease, either as injection or nasal spray, is a therapeutic alternative to bisphosphonates [68–70] The efficacy and safety of SCT in Paget’s disease was established in a number of primarily observational studies initiated in the 1970s and 1980s.”
BackgroundIs Calcitonin an Important Physiological Substance?
Hirsch, P. F., & Baruch, H. (2003) · Endocrine · doi:10.1385/endo:21:3:201 · Cited by 73 · cited 1×
“Initial findings of osteopenia in calcitonin knockout mice (CT/CGRP) [4] were not corroborated [5], and no bone pathologies have been associated with hypo- or hypersecretion of calcitonin in humans [6].”
Background(1984) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a067808 · Cited by 68 · cited 1×
“An increase in renal calcium excretion has also been described and may contribute to the fast onset of the calcium-lowering effect of SCT in hypercalcemic stages [11, 12].”
BackgroundAnalgesic Efficacy of Calcitonin for Vertebral Fracture Pain
Blau, L. A., & Hoehns, J. D. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c350 · Cited by 67 · cited 1×
“[94] found that in 13 out of 14 placebo-controlled trials statistically significant improvement in vertebral fracture pain or function related endpoints was reported for the calcitonin-treated patients (with various SCT formulations).”
BackgroundReginster, J. Y., Denis, D., Deroisy, R., Lecart, M. P., de Longueville, M., Zegels, B., Sarlet, N., Noirfalisse, P., & Franchimont, P. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090110 · Cited by 66 · cited 1×
“Studies in early menopausal women have typically shown a stabilization of BMD at the lumbar spine [46, 47].”
BackgroundCalcitonin promotes osteoclast survival in vitro
Selander, K. S., Härkönen, P. L., Valve, E. M., Mönkkönen, J., Hannuniemi, R., & Väänänen, H. K. (1996) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(96)03870-1 · Cited by 65 · cited 1×
“Cell apoptosis has not been observed with calcitonin for either osteoclasts, osteoblasts or osteocytes [19, 20].”
BackgroundCalcitonin is involved in cartilage homeostasis: Is calcitonin a treatment for OA?
Karsdal, M. A., Tankó, L. B., Riis, B. J., Søndergaard, B. C., Henriksen, K., Altman, R. D., Qvist, P., & Christiansen, C. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.03.014 · Cited by 64
Treatment of Postmenopausal Osteoporosis
Altkorn, D., & Vokes, T. (2001) · JAMA · doi:10.1001/jama.285.11.1415 · Cited by 63
Effects of calcitonin on bone quality and osteoblastic function
Wallach, S., Farley, J. R., Baylink, D. J., & Brenner-Gati, L. (1993) · Calcified Tissue International · doi:10.1007/bf00310194 · Cited by 52 · cited 1×
“The existence of calcitonin receptors on osteoblasts has been suggested [21–24], and findings in some clinical trials have indicated a possible stimulatory effect on bone formation.”
BackgroundGoals of treatment for paget's disease of bone
Siris, E. S. (1999) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650140211 · Cited by 49 · cited 1×
“At present SCT constitutes a valid second line treatment option for patients with Paget’s disease who do not tolerate bisphosphonates or for whom bisphosphonates are not effective due to secondary resistance [77].”
BackgroundHuusko, T., Karppi, P., Kautiainen, H., Suominen, H., Avikainen, V., & Sulkava, R. O. (2002) · Calcified Tissue International · doi:10.1007/s00223-001-2111-x · Cited by 41 · cited 1×
“Analgesic effects for SCT-NS have also been investigated in the postoperative setting following femoral/hip arthroplasty [90, 91].”
BackgroundJiang, Y., Zhao, J., Geusens, P., Liao, E.-Y., Adriaensens, P., Gelan, J., Azria, M., Boonen, S., Caulin, F., Lynch, J. A., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041008 · Cited by 41 · cited 1×
“Furthermore, in a recent study, MRI has demonstrated a significant positive effect of SCT on compressive stress and on trabecular microarchitecture in an animal model [56].”
BackgroundSelf-citationEquivalence of Nasal Spray and Subcutaneous Formulations of Salmon Calcitonin
Combe, B. G., Cohen, C., & Aubin, F. (1997) · Calcified Tissue International · doi:10.1007/s002239900284 · Cited by 40 · cited 1×
“Overall, the pain relieving effects of nasal spray and injectable SCT appear comparable [92, 93].”
BackgroundTóth, E., Csupor, E., Mészáros, S., Ferencz, V., Németh, L., McCloskey, E. V., & Horváth, C. (2004) · Bone · doi:10.1016/j.bone.2004.09.003 · Cited by 39 · cited 1×
“In 2 placebocontrolled trials over 12 or 18 months (n=28 and n=40) [63, 64], SCT-NS led to statistically significant increases in lumbar spine BMD when compared to placebo.”
BackgroundRole of serotonin in the analgesic activity of calcitonin
Clementi, G., Prato, A., Conforto, G., & Scapagnini, U. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90298-x · Cited by 38 · cited 1×
“Numerous calcitonin binding sites have been detected in the CNS, especially in the hypothalamus [78–80], and it is therefore assumed that the analgesic effects of salmon calcitonin are at least to some extent mediated centrally, with serotonergic pathways involved [81–83].”
BackgroundMedical Management of Hypercalcemia
Ralston, S. H., Coleman, R. E., Wd, F., Gallagher, S. J., Hosking, D. J., Iqbal, J., McCloskey, E. V., & Sampson, D. (2003) · Calcified Tissue International · doi:10.1007/s00223-001-1135-6 · Cited by 38 · cited 1×
“An increase in renal calcium excretion has also been described and may contribute to the fast onset of the calcium-lowering effect of SCT in hypercalcemic stages [11, 12].”
BackgroundRationale for the potential use of calcitonin in osteoarthritis.
Manicourt, D.-H., Devogelaer, J. P., Azria, M., & Silverman, S. L. (2005) · PubMed · Cited by 38
Self-citationNakamura, M., Morimoto, S., Zhang, Z., Utsunomiya, H., Inagami, T., Ogihara, T., & Kakudo, K. (2001) · Calcified Tissue International · doi:10.1007/s002230001215 · Cited by 37 · cited 1×
“An association has been described between specific calcitonin gene receptor genotypes and phenotypes of modestly increased bone mineral density (BMD) in Japanese populations [30] and in patients with juvenile idiopathic arthritis [31].”
BackgroundYumita, S., Professor Nicholson, G. C., Rowe, D. J., Kent, G. N., & Martin, T. J. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060610 · Cited by 36 · cited 1×
“Flattening of the osteoclast ruffled borders and withdrawal of osteoclasts from sites of active bone resorption occurs upon exposure to calcitonin in vitro [14–18].”
BackgroundManaging acute osteoporotic vertebral fractures with calcitonin.
Maksymowych, W. P. (1998) · PubMed Central · Cited by 35
Masi, L., Cimaz, R., Simonini, G., Bindi, G., Stagi, S., Gozzini, A., Malentacchi, C., Brandi, M. L., & Falcini, F. (2002) · PubMed · Cited by 35
Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse
Colado, M. I., Ormazábal, M. J., Goicoechea, C., López, F. M., Alfaro, M. J., & Martín, M. I. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90175-9 · Cited by 34 · cited 1×
“Numerous calcitonin binding sites have been detected in the CNS, especially in the hypothalamus [78–80], and it is therefore assumed that the analgesic effects of salmon calcitonin are at least to some extent mediated centrally, with serotonergic pathways involved [81–83].”
BackgroundWoodhouse, N. J. Y., Chalmers, A. H., Wells, I. P., Dewbury, K. C., & Mohamedally, S. M. (1977) · British Journal of Radiology · doi:10.1259/0007-1285-50-598-699 · Cited by 31
Peichl, P., Marteau, R., Griesmacher, A., Kumpan, W., Schedl, R., Prosquil, E., Fasol, P., & Br�ll, H. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0591-2 · Cited by 29 · cited 1×
“Analgesic effects for SCT-NS have also been investigated in the postoperative setting following femoral/hip arthroplasty [90, 91].”
BackgroundSynthetic Salmon Calcitonin: Treatment of Paget's Disease and Osteogenesis Imperfecta
Goldfield, E. B. (1972) · JAMA · doi:10.1001/jama.1972.03200230015004 · Cited by 26
Lufkin, E. G., Sarkar, S., Kulkarni, P. M., Ciaccia, A. V., Siddhanti, S. R., Stock, J. L., & Plouffe, L. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003071 · Cited by 26
Review of Treatment Modalities for Postmenopausal Osteoporosis
Hamdy, R. C., Chesnut, C. H., Gass, M. L. S., Holick, M. F., Leib, E. S., Lewiecki, M. E., Maricic, M. J., & Watts, N. B. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000184921.53062.bf · Cited by 25 · cited 1×
“Comparisons across different trials and pooled analysis have been presented by a number of authors [57– 61]; however, interpretation of these data has not been uniform.”
ResultSelf-citationEffect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women
Meschìa, M., Brincat, M., Barbacini, P., Maini, M. C., Marri, R., & Crosignani, P. G. (1992) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0028-2243(92)90214-j · Cited by 24 · cited 1×
“Effects on lumbar spine BMD have been reported in a number of smaller controlled clinical trials [34–36].”
BackgroundPAGET'S DISEASE OF BONE EXPERIENCES WITH 100 PATIENTS TREATED WITH SALMON CALCITONIN ∗
Grunstein, H. S., Clifton-Bligh, P. B., & Posen, S. (1981) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1981.tb128316.x · Cited by 24
Bone-Anabolic Effect of Salmon Calcitonin on Glucocorticoid-Induced Osteopenia in Rats.
Furuichi, H., Fukuyama, R., Izumo, N., Fujita, T., Kohno, T., Nakamuta, H., & Koida, M. (2000) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.23.946 · Cited by 22 · cited 1×
“The existence of calcitonin receptors on osteoblasts has been suggested [21–24], and findings in some clinical trials have indicated a possible stimulatory effect on bone formation.”
BackgroundHistologic changes in Paget's disease treated with calcitonin
Fornasier, V., Stapleton, K., & Williams, C. C. (1978) · Human Pathology · doi:10.1016/s0046-8177(78)80030-6 · Cited by 21 · cited 1×
“Positive clinical effects of SCT included reductions in bone pain [71], bone turnover markers [72], improved bone structure assessed by radiography [73] and histology [74, 75] and a reduction in the incidence of pathological fractures [76].”
BackgroundClissold, S. P., Fitton, A., & Chrisp, P. (1991) · Drugs & Aging · doi:10.2165/00002512-199101050-00007 · Cited by 20 · cited 1×
“In earlier studies, these local reactions were reported in fewer than 10% of patients receiving SCT-NS [ 99 , 100].”
BackgroundLong-term tolerability of nasal spray formulation of salmon calcitonin
Foti, R., Martorana, U., & Broggini, M. (1995) · Current Therapeutic Research · doi:10.1016/0011-393x(95)85012-0 · Cited by 19 · cited 1×
“In earlier studies, these local reactions were reported in fewer than 10% of patients receiving SCT-NS [99, 100].”
BackgroundAcute effects of nasal salmon calcitonin on calcium and bone metabolism
Thamsborg, G., Skousgaard, S. G., Daugaard, H., Schifter, S. O. R., Kollerup, G., & Sørensen, O. H. (1993) · Calcified Tissue International · doi:10.1007/bf01320907 · Cited by 19 · cited 1×
“In healthy subjects with normal calcium levels only subtle, transient calcium-lowering effects are observed following the administration of SCT [7, 8].”
BackgroundZikán, V., & Stepan, J. J. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00731-8 · Cited by 19 · cited 1×
“showed a maximum suppression of 55% within 1 hour of SCT-NS administration [39], which was reversible over 24 hours.”
Background[Calcitonin in acute pain due to vertebral fracture in osteoporosis. Cooperative study].
Arinoviche, R., Arriagada, M., Jacobelli, S. H., Massardo, L., Rivero, S. A. G., Aris, H., Valenzuela, M., Rojas, C., Carvallo, A., V, & Gatica, H. (1987) · PubMed · Cited by 16
Molecular and Clinical Pharmacology of Calcitonin
Zaidi, M., Inzerillo, A. M., Troen, B. R., Moonga, B. S., Abe, E., & Burckhardt, P. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50184-0 · Cited by 16 · cited 1×
“The calciumlowering effect is primarily due to the reduction of bone resorption by inhibition of osteoclast activity, as well as possibly osteoclast number and secretory activity [10].”
BackgroundSrivastava, A. K., Libanati, C. R., Hohmann, O., Kriegman, A. G., & Baylink, D. J. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0036-x · Cited by 11 · cited 2×
“[40]) Osteoporos Int (2008) 19:479–491 481”
Calcitonin for multiple fractures in Paget's disease.
Evans, G. A., & Slee, G. C. (1977) · BMJ · doi:10.1136/bmj.1.6057.357 · Cited by 10 · cited 1×
“Positive clinical effects of SCT included reductions in bone pain [71], bone turnover markers [72], improved bone structure assessed by radiography [73] and histology [74, 75] and a reduction in the incidence of pathological fractures [76].”
BackgroundRico, H., Hernández, E. R., Younes, M., Hernández, D., & Espinos, D. (1988) · Bone · doi:10.1016/8756-3282(88)90028-2 · Cited by 9 · cited 1×
“Positive clinical effects of SCT included reductions in bone pain [71], bone turnover markers [ 72 ], improved bone structure assessed by radiography [73] and histology [74, 75] and a reduction in the incidence of pathological fractures [76].”
BackgroundDelling, G. R., Schulz, A., & Ziegler, R. (1976) · Calcified Tissue International · doi:10.1007/bf02064100 · Cited by 7 · cited 1×
“Positive clinical effects of SCT included reductions in bone pain [71], bone turnover markers [72], improved bone structure assessed by radiography [73] and histology [74, 75] and a reduction in the incidence of pathological fractures [76].”
BackgroundBehandlung der Osteodystrophia deformans Paget mit Lachs-Calcitonin*
Kuhlencordt, F., Ringe, J. D., & Kruse, H. ‐. (2008) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2008-1070566 · Cited by 7 · cited 1×
“In addition a number of non-controlled studies have indicated that injectable calcitonin provides analgesic effects in Paget‘s disease [88, 89].”
Background
Research works printed but not linked: 8
- Woodrow JP, Noseworthy CS, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS (2003) Calcitonin/calcitonin gene-related peptide protect the maternal skeleton from excessive resorption during lactation [abstract]. J Bone Miner Res 18(Suppl 2):S37
- Hoff A, Thomas M, Cote G (1998) Generation of a calcitonin knockout mouse model [abstract]. Bone 23:1062
- Voss A, Liese S, Priemel M, Catala-Lehnen P, Schilling AF, Mueldner C, Haberland M, Rueger JM, Emeson RB, Gagel RF, Schinke T, Amling M (2005) Uncovering the physiologic function of calcitonin using genetically modified mouse models [abstract]. J Bone Min Res (Suppl.):1162
- Chesnut CH, Richardson P, Mindeholm L (2002) Salmon calcitonin nasal spray (SCNS): effect on hip fractures in postmenopausal women [abstract]. Osteoporos Int 13(Suppl 1):128
- Olson M, Mindeholm L, Eriksen EF, Majumdar S, Azria M, Chesnut C (2006) Trabecular number as risk factor in osteoporosis and the role of nasal spray calcitonin (NS-CT) in its modification [abstract]. Osteoporos Int 17(Suppl 1):S12–S13
- Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, Tugwell P, Wells G (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD001983
- Gennari C, Agnusdei D (1988) Calcitonin in bone pain management. Curr Ther Res 44:712–722
- Gennari C, Chierichetti SM, Piolini M, Vibelli C, Agnusdei D, Civitelli R, Gonelli S (1985) Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study. Curr Ther Res 38:298–308
Cited by
Nutritional Value of Fish: Lipids, Proteins, Vitamins, and Minerals
Khalili Tilami, S., & Sampels, S. (2018) · Reviews in Fisheries Science & Aquaculture · doi:10.1080/23308249.2017.1399104 · Cited by 488
Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules
Chen, M.-C., Mi, F.-L., Liao, Z.-X., Hsiao, C.-W., Sonaje, K., Chung, M.-F., Hsu, L.-W., & Sung, H.-W. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.010 · Cited by 451
“Calcitonin, a peptide hormone of 32 amino acids, has been administered formany years to lower blood calcium and treat bone diseases, including osteoporosis and Paget's disease [146].”
BackgroundWitten, P. E., & Huysseune, A. (2009) · Biological Reviews · doi:10.1111/j.1469-185x.2009.00077.x · Cited by 362
“Salmon calcitonin is an established antiresorptive osteoporosis medication (Chesnut et al., 2008) and appears to have a similar effect in fish.”
BackgroundPEG-based thermosensitive and biodegradable hydrogels
Shi, J., Yu, L., & Ding, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.009 · Cited by 341
Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts
Moroz, E., Matoori, S., & Leroux, J.-C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.010 · Cited by 336
Metadata
- Authors
- Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L.
- Affiliations
- University of Washington (US)
- Novartis (Switzerland) (CH)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Chesnut, C. H.
- Venue
- Osteoporosis International
- Published
- 2007-12-11
- Volume
- 19
- Issue
- 4
- Pages
- 479-491
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2069365129
- Cited by
- 216
- References
- 106
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 8 · 2023: 10 · 2022: 17 · 2021: 7 · 2020: 15 · 2019: 10 · 2018: 12 · 2017: 15 · 2016: 12 · 2015: 7 · 2014: 11 · 2013: 14 · 2012: 9
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- salmon calcitonin, osteoporosis, Paget's disease, osteoarthritis, postmenopausal osteoporosis, bone quality, chondroprotection, metabolic bone disease
- MeSH terms
- Adult, Aged, Bone Resorption, Calcitonin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Middle Aged, Osteitis Deformans, Parathyroid Hormone, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.